Cantor Fitzgerald Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD)

Cantor Fitzgerald started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday morning, MarketBeat.com reports. The firm issued an overweight rating and a $50.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Aardvark Therapeutics’ FY2024 earnings at ($3.89) EPS and FY2025 earnings at ($2.49) EPS.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD opened at $10.14 on Monday. Aardvark Therapeutics has a 12 month low of $9.21 and a 12 month high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other news, CFO Nelson Sun bought 10,000 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was purchased at an average cost of $16.00 per share, with a total value of $160,000.00. Following the acquisition, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Tien-Li Lee bought 16,542 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were purchased at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the acquisition, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.